围手术期HbA1c对接受全髋关节置换术的糖尿病患者报销费用的影响:一项全国性分析
该研究回顾性查询2007至2015年Humana保险索赔数据库,纳入全髋关节置换术(THA)前后3个月内检测过HbA1c的糖尿病患者,按HbA1c从5.5%起以1%递增分层至11.5%,另设11.5%-20%组,分析HbA1c与手术当日、术后89天及全局90天费用的相关性。结果显示HbA1c与手术当日费用(相关系数=0.664)、术后89天费用(相关系数=0.789)及全局90天费用(相关系数=0.747)显著相关,且费用随HbA1c升高而显著增加(P < .0001)。
要点
- HbA1c与THA手术当日费用显著相关(相关系数=0.664)。
- HbA1c与THA术后89天费用显著相关(相关系数=0.789)。
- HbA1c与THA全局90天费用显著相关(相关系数=0.747)。
核心结论
- 较高的围手术期HbA1c水平增加THA的手术当日、术后89天及全局90天费用,作者认为这与患者需要多学科照护、住院时间更长及并发症更多有关,并认为有必要基于血糖控制进一步研究术后并发症。
研究设计与样本
- 回顾性查询Humana保险索赔数据库2007至2015年所有接受THA的糖尿病患者,仅纳入THA前后3个月内检测过HbA1c(%)者,按HbA1c从5.5%起以1%递增至11.5%分为6组,另设11.5%-20%组分析极端病例,分析HbA1c与手术当日、术后89天及全局90天报销费用的相关性。
主要发现
- HbA1c水平与手术当日费用显著相关(相关系数=0.664)。
- HbA1c水平与术后89天费用显著相关(相关系数=0.789)。
- HbA1c水平与全局90天费用显著相关(相关系数=0.747)。
- 手术当日、术后89天及全局90天费用随HbA1c水平升高而显著增加(P < .0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who have diabetes mellitus (DM) are at an increased risk of postoperative complications following total hip arthroplasty (THA). Therefore, much interest has been paid to perioperative glycemic control. However, no prior studies have evaluated the patient variation of HbA1c levels on costs. Therefore, the purpose of this study was to evaluate the impact of obtaining preoperative HbA1c levels on (1) day of surgery (DOS) cost; (2) subsequent 89-day costs; and (3) global 90-day cost. METHODS: A retrospective query of the Humana insurance claims database was performed from 2007 to 2015 for all DM patients undergoing THA. Only patients with HbA1c (%) levels within 3 months before or after the THA were included. Patients were stratified into 6 groups based on HbA1c starting at 5.5% and increasing by 1% increments to 11.5%; one additional group (11.5%-20%) for extreme cases was analyzed. Correlations between HbA1c level and reimbursements for DOS, subsequent 89-day, and global 90-day period were performed. RESULTS: HbA1c level demonstrated a significant correlation to DOS (correlation coefficient = 0.664), subsequent 89-day (correlation coefficient = 0.789), and global 90-day period (correlation coefficient = 0.747) costs. DOS, 89-day, and global 90-day costs significantly increased with increasing HbA1c levels (P < .0001). CONCLUSION: Higher perioperative HbA1c levels increase the DOS, subsequent 89-day, and global 90-day costs of THA. This was expected as these patients require multidisciplinary care, have longer LOS, and develop more complications. Further investigation into postoperative complications based on glycemic control is warranted.
引用
- Kurowicki J, Rosas S, Khlopas A, et al. Impact of Perioperative HbA1c on Reimbursements in Diabetes Mellitus Patients Undergoing Total Hip Arthroplasty: A Nationwide Analysis. J Arthroplasty. 2018. PMID: 29891083. doi:10.1016/j.arth.2018.01.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。